Latest News-Zhongshan Kangfang Biological Medicine Co., LTD Mediaroom_Page

Akeso's Cadonilimab (PD-1/CTLA-4), the First Dual Immune Checkpoint Inhibitor to Treat Cancer, Approved for Marketing in China

* Globally first dual immune checkpoint inhibitor bi-specific antibody approved for marketing *...

2022-06-29 20:14 2014

Akeso releases promising data of Ivonescimab (PD-1/VEGF BsAbs, AK112) for advanced NSCLC at ASCO 2022

HONG KONG, June 5, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmac...

2022-06-06 09:00 1772

Akeso announces oral presentation featuring promising clinical data of Cadonilimab (PD-1/CTLA-4 BsAbs, AK104) for the first-line treatment of R/M cervical cancer at ASCO 2022

HONG KONG, June 5, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmac...

2022-06-06 09:00 1552

Akeso releases promising data of Ivonescimab (PD-1/VEGF BsAbs, AK112) combined with chemotherapy in advanced NSCLC at ASCO 2022

HONG KONG, June 5, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmac...

2022-06-06 09:00 1739

Akeso Publishes Preclinical Results of PD-1/LAG-3 Bi-specific Antibody（AK129）at the American Association for Cancer Research (AACR) 2022 Annual Meeting

HONG KONG, April 14, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharm...

2022-04-14 15:39 1921

Akeso Publishes Preclinical Results of PD-1/CD73 Bi-specific Antibody（AK131）at the American Association for Cancer Research (AACR) 2022 Annual Meeting

HONG KONG, April 14, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharm...

2022-04-14 15:05 1702

Akeso Publishes Preclinical Results of TIGIT monoclonal antibody（AK127）at the American Association for Cancer Research (AACR) 2022 Annual Meeting

HONG KONG, April 14, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharm...

2022-04-14 14:54 1923

Akeso Reported 2021 Annual Results

Penpulimab Started Commercialization and Cadonilimab Filed for NDA HONG KONG, April 1, 2022 /PRNews...

2022-04-01 13:44 24793

Akeso Announces IND Approval from China NMPA for Phase II Clinical Trial of Cadonilimab in Combination with Docetaxel to Treat NSCLC

HONG KONG, March 7, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), a biopharmaceutical compa...

2022-03-08 11:49 1770

Akeso Announces Clinical Trial Collaboration with Chipscreen Biosciences to Evaluate Cadonilimab in Combination with Chiauranib for Extensive-Stage Small-Cell Lung Cancer

HONG KONG, March 2, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), a biopharmaceutical compa...

2022-03-03 01:34 2141

AKESO'S NGF MONOCLONAL ANTIBODY (AK115) APPROVED TO INITIATE CLINICAL TRIAL IN PAIN (INCLUDING CANCER PAIN)

HONG KONG, Feb. 10, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the clinical trial ap...

2022-02-10 17:00 1917

AKESO'S LIGUFALIMAB AND IVONESCIMAB OBTAINED APPROVAL TO INITIATE A PHASE II TRIAL

HONG KONG, Jan. 30, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announces that the Ligufalimab (CD47...

2022-01-31 10:14 2177

AKESO DOSES FIRST PATIENT IN THE PHASE III TRIAL OF IVONESCIMAB COMBINED WITH CHEMOTHERAPY IN EGFR-TKI RESISTANT EGFR MUTATION ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

HONG KONG, Jan. 30, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announces that the first patient was...

2022-01-31 09:51 2076

Akeso's AK117 (CD47 monoclonal antibody) in Combination with AK112 (PD-1/VEGF bi-specific antibody) to Initiate a Phase Ib/II Clinical Trial with or without Chemotherapy for the Treatment of Advanced Malignant Tumors

HONG KONG, Jan. 18, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announces that Ligufalimab (CD47 mon...

2022-01-18 20:44 2002

AKESO'S CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) COMBINED WITH IVONESCIMAB (PD-1/VEGF BI-SPECIFIC ANTIBODY) COMBINED WITH OR WITHOUT CHEMOTHERAPY OBTAINED APPROVAL TO INITIATE A PHASE Ib/II CLINICAL TRIAL FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER

HONG KONG, Jan. 6, 2022 /PRNewswire/ -- Today, Akeso, Inc. (09926.HK) announces that Cadonilimab (P...

2022-01-06 19:00 2284

AKESO'S CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) COMBINED WITH CONCURRENT CHEMORADIOTHERAPY OBTAINED APPROVAL TO INITIATE A PHASE III CLINICAL TRIAL FOR THE TREATMENT OF LOCALLY ADVANCED CERVICAL CANCER

HONG KONG, Jan. 3, 2022 /PRNewswire/ -- Today, Akeso (09926.HK) announces that Cadonilimab (PD-1/ C...

2022-01-04 10:00 2349

Akeso's IL-17A MONOCLONAL ANTIBODY (GUMOKIMAB) COMPLETION OF PATIENT ENROLLMENT IN PHASE II CLINICAL TRIAL FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS

HONG KONG, Dec. 27, 2021 /PRNewswire/ -- Today, Akeso, Inc. (09926.HK) announces that Gumokimab (I...

2021-12-28 12:30 2037

Akeso's PCSK9 MONOCLONAL ANTIBODY (EBRONUCIMAB) EARLY COMPLETION OF PATIENT ENROLLMENT IN A PHASE III CLINICAL TRIAL FOR PRIMARY HYPERCHOLESTEROLEMIA AND MIXED HYPERLIPIDEMIA

HONG KONG, Dec. 22, 2021 /PRNewswire/ -- Today, Akeso, Inc. (09926.HK) announces that Ebronucimab (...

2021-12-23 12:42 2316

Akeso Announces Launch of U.S. Investigator-Initiated Study of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody)

HONG KONG, Dec. 6, 2021 /PRNewswire/ -- Today, Akeso, Inc. (9926.HK) announced that the company wil...

2021-12-07 08:20 1935

PD-1/VEGF Bi-Specific Antibody (AK112) Obtained Approval to Initiate a Phase II Clinical Trial for Monotherapy or Combined Chemotherapy Neoadjuvant/Adjuvant Therapy of Resectable Non-Small Cell Lung Cancer

HONG KONG, Nov. 2, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that AK112 (PD...

2021-11-02 11:53 1752